

Jean-Yves Reginster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/617686/publications.pdf>

Version: 2024-02-01

345
papers

39,286
citations

8208

78
h-index

3508

188
g-index

360
all docs

360
docs citations

360
times ranked

31445
citing authors

#	ARTICLE	IF	CITATIONS
1	Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 223-234.	1.4	16
2	Neurofilament light chain concentration in an aging population. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 331-339.	1.4	32
3	Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 481-483.	1.4	14
4	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	1.4	33
5	Quality of life and sarcopenic patients.. <i>Geriatric Et Psychologie Neuropsychiatrie Du Vieillessement</i> , 2022, , .	0.0	0
6	Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1613-1625.	1.4	3
7	Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 1119-1128.	1.1	1
8	Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3-17.	1.4	46
9	Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 37-47.	1.4	32
10	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. <i>Pharmacoeconomics</i> , 2021, 39, 181-209.	1.7	63
11	Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. <i>Clinical Nutrition</i> , 2021, 40, 2188-2199.	2.3	24
12	Impact of Malnutrition Status on Muscle Parameter Changes over a 5-Year Follow-Up of Community-Dwelling Older Adults from the SarcoPhAge Cohort. <i>Nutrients</i> , 2021, 13, 407.	1.7	20
13	The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). <i>Arthritis Research and Therapy</i> , 2021, 23, 12.	1.6	3
14	Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL Â® questionnaire. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 319-330.	2.9	8
15	2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1149-1156.	1.4	8
16	Expertsâ€™ preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1079-1083.	1.4	3
17	P113â€fHow has COVID-19 affected the treatment of osteoporosis? The answers from a global survey. <i>Rheumatology</i> , 2021, 60, .	0.9	0
18	Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. <i>Current Aging Science</i> , 2021, 14, 242-248.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1507-1517.	1.4	18
20	Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 405.	0.9	3
21	2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2141-2147.	1.4	12
22	Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey. <i>Archives of Osteoporosis</i> , 2021, 16, 103.	1.0	3
23	Assessment of the performance of the SarQoL [®] questionnaire in screening for sarcopenia in older people. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2149-2155.	1.4	6
24	A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8980.	1.8	15
25	Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial. <i>Rheumatology and Therapy</i> , 2021, 8, 1617-1636.	1.1	14
26	Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study. <i>European Geriatric Medicine</i> , 2021, , 1.	1.2	0
27	Fracture Risk Assessment and How to Implement a Fracture Liaison Service. <i>Practical Issues in Geriatrics</i> , 2021, , 241-256.	0.3	6
28	The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. <i>Archives of Osteoporosis</i> , 2021, 16, 179.	1.0	2
29	Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 804560.	1.5	8
30	Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. <i>Disability and Rehabilitation</i> , 2020, 42, 2076-2082.	0.9	4
31	Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. <i>Clinical Rheumatology</i> , 2020, 39, 861-871.	1.0	67
32	Outcome Priorities for Older Persons With Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 267-271.e2.	1.2	13
33	Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 284-286.	1.2	6
34	Prediction of Adverse Outcomes in Nursing Home Residents According to Intrinsic Capacity Proposed by the World Health Organization. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1594-1599.	1.7	73
35	Influence of bone mineral density in circulating adipokines among postmenopausal Arab women. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 374-379.	1.8	9
36	Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. <i>Clinical Nutrition ESPEN</i> , 2020, 35, 47-62.	0.5	41

#	ARTICLE	IF	CITATIONS
37	Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study. <i>Calcified Tissue International</i> , 2020, 106, 239-247.	1.5	22
38	Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. <i>Rheumatology and Therapy</i> , 2020, 7, 703-740.	1.1	24
39	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 859-866.	1.6	7
40	Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1200-1211.	2.9	55
41	Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. <i>Nutrients</i> , 2020, 12, 3485.	1.7	15
42	Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. <i>Advances in Therapy</i> , 2020, 37, 4641-4648.	1.3	2
43	The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study. <i>Experimental Gerontology</i> , 2020, 138, 110983.	1.2	11
44	Motivational climate of group exercise sessions in nursing homes. <i>Archives of Public Health</i> , 2020, 78, 43.	1.0	3
45	Physical performance trajectories and mortality among nursing home residents: results of the SENIOR cohort. <i>Age and Ageing</i> , 2020, 49, 800-806.	0.7	10
46	Senior physical activity contests in nursing homes: a feasibility study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 869-876.	1.4	2
47	Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 394-400.	1.6	14
48	The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 334-335.	0.5	2
49	Glucosamine sulphate: an umbrella review of health outcomes. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097592.	1.2	14
50	Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties. <i>Annals of Geriatric Medicine and Research</i> , 2020, 24, 139-147.	0.7	9
51	Assessment of the energy expenditure of Belgian nursing home residents using indirect calorimetry. <i>Nutrition</i> , 2019, 57, 12-16.	1.1	4
52	Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 43-46.e2.	1.2	31
53	Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. <i>Arthritis Care and Research</i> , 2019, 71, 300-307.	1.5	5
54	Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1375-1389.	1.4	53

#	ARTICLE	IF	CITATIONS
55	East meets West: current practices and policies in the management of musculoskeletal aging. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1351-1373.	1.4	32
56	Energy Expenditure of Nursing Home Residents and Participation in Exercise Classes: An Analysis of the SENIOR Cohort. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1183-1184.	1.2	2
57	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). <i>Ageing Research Reviews</i> , 2019, 55, 100946.	5.0	103
58	Relationship between peak expiratory flow and incidence of frailty, deaths and falls among nursing home residents: Results of the SENIOR cohort. <i>Archives of Gerontology and Geriatrics</i> , 2019, 85, 103913.	1.4	12
59	Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1163-1167.	1.4	21
60	Redesigning care for older people to preserve physical and mental capacity: WHO guidelines on community-level interventions in integrated care. <i>PLoS Medicine</i> , 2019, 16, e1002948.	3.9	57
61	Using supervised learning machine algorithm to identify future fallers based on gait patterns: A two-year longitudinal study. <i>Experimental Gerontology</i> , 2019, 127, 110730.	1.2	11
62	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 899-911.	5.5	111
63	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019, 36, 2811-2824.	1.3	60
64	Sarcopenia and health-related outcomes: an umbrella review of observational studies. <i>European Geriatric Medicine</i> , 2019, 10, 853-862.	1.2	59
65	Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1182-1183.	1.2	16
66	Relationship between the changes over time of bone mass and muscle health in children and adults: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 429.	0.8	22
67	Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. <i>Rheumatology International</i> , 2019, 39, 1117-1123.	1.5	16
68	Metabolic Syndrome in Arab Adults with Low Bone Mineral Density. <i>Nutrients</i> , 2019, 11, 1405.	1.7	20
69	Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL [®]). <i>European Geriatric Medicine</i> , 2019, 10, 761-767.	1.2	15
70	Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 25-44.	1.3	56
71	Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 129-143.	1.3	57
72	Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1057-1067.	1.4	15

#	ARTICLE	IF	CITATIONS
73	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. <i>Drugs and Aging</i> , 2019, 36, 15-24.	1.3	146
74	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Drugs and Aging</i> , 2019, 36, 145-159.	1.3	15
75	Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 101-127.	1.3	53
76	Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 65-99.	1.3	70
77	Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 45-64.	1.3	62
78	Importance of Safety in the Management of Osteoarthritis and the Need for Updated Meta-Analyses and Recommendations for Reporting of Harms. <i>Drugs and Aging</i> , 2019, 36, 3-6.	1.3	2
79	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. <i>Calcified Tissue International</i> , 2019, 105, 109-124.	1.5	51
80	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	1.4	47
81	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 337-350.	1.6	392
82	Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. <i>PLoS ONE</i> , 2019, 14, e0216065.	1.1	32
83	Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. <i>Women's Health</i> , 2019, 15, 174550651984404.	0.7	488
84	The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 753-758.	1.4	33
85	Practical guidance for patient-centred health research. <i>Lancet, The</i> , 2019, 393, 1095-1096.	6.3	27
86	Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. <i>Advances in Therapy</i> , 2019, 36, 1085-1099.	1.3	49
87	Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 815-824.	1.4	57
88	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. <i>Calcified Tissue International</i> , 2019, 105, 1-14.	1.5	295
89	Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 881-887.	1.4	15
90	Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 184-196.	1.6	30

#	ARTICLE	IF	CITATIONS
91	Malnutrition as a Strong Predictor of the Onset of Sarcopenia. <i>Nutrients</i> , 2019, 11, 2883.	1.7	129
92	Mediterranean diet and knee osteoarthritis outcomes: A longitudinal cohort study. <i>Clinical Nutrition</i> , 2019, 38, 2735-2739.	2.3	38
93	The health economics burden of sarcopenia: a systematic review. <i>Maturitas</i> , 2019, 119, 61-69.	1.0	134
94	EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 384-385.	1.2	57
95	Patients' preferences for osteoarthritis treatment: the value of stated-preference studies. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1-3.	1.4	23
96	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 9-19.	1.6	110
97	Impact du traitement par statines dans la progression radiologique de la gonarthrose: résultats issus de l'analyse post-hoc de l'essai SEKOIA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 81-86.	0.0	0
98	Sarcopenia: revised European consensus on definition and diagnosis. <i>Age and Ageing</i> , 2019, 48, 16-31.	0.7	6,824
99	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 19-30.	1.4	31
100	Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort. <i>Calcified Tissue International</i> , 2019, 104, 273-284.	1.5	29
101	Coexistence of Pre-sarcopenia and Metabolic Syndrome in Arab Men. <i>Calcified Tissue International</i> , 2019, 104, 130-136.	1.5	9
102	The relationship between the dietary inflammatory index and prevalence of radiographic symptomatic osteoarthritis: data from the Osteoarthritis Initiative. <i>European Journal of Nutrition</i> , 2019, 58, 253-260.	1.8	30
103	Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 376-385.	0.9	17
104	Normative data for isometric strength of 8 different muscle groups and their usefulness as a predictor of loss of autonomy among physically active nursing home residents: the SENIOR cohort. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019, 19, 258-265.	0.1	5
105	Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212460.	0.5	2
106	Comparison of the performance of five screening methods for sarcopenia. <i>Clinical Epidemiology</i> , 2018, Volume 10, 71-82.	1.5	80
107	Evidence for the Domains Supporting the Construct of Intrinsic Capacity. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1653-1660.	1.7	366
108	Sarcopenic osteoarthritis: a new entity in geriatric medicine?. <i>European Geriatric Medicine</i> , 2018, 9, 141-148.	1.2	14

#	ARTICLE	IF	CITATIONS
109	Pitfalls in the measurement of muscle mass: a need for a reference standard. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 269-278.	2.9	482
110	Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. <i>Cartilage</i> , 2018, 9, 127-139.	1.4	24
111	Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. <i>European Geriatric Medicine</i> , 2018, 9, 23-28.	1.2	32
112	Promoting the consumption of dairy products for fracture prevention: A good value for money?. <i>Joint Bone Spine</i> , 2018, 85, 403-404.	0.8	2
113	Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 147-160.	0.7	13
114	French translation and validation of the sarcopenia screening tool SARC-F. <i>European Geriatric Medicine</i> , 2018, 9, 29-37.	1.2	29
115	Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the "need for surgery". <i>Aging Clinical and Experimental Research</i> , 2018, 30, 315-321.	1.4	16
116	Quality of life assessment in musculo-skeletal health. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 413-418.	1.4	144
117	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>Joint Bone Spine</i> , 2018, 85, 609-614.	0.8	29
118	The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 191-195.	0.7	6
119	Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2018, 30, 111-117.	1.4	56
120	Quality of life in sarcopenia measured with the SarQoL [®] : impact of the use of different diagnosis definitions. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 307-313.	1.4	64
121	Prediction of the Incidence of Falls and Deaths Among Elderly Nursing Home Residents: The SENIOR Study. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 18-24.	1.2	56
122	The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al.. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1272-1274.	2.9	9
123	Polish Validation of the SarQoL [®] , a Quality of Life Questionnaire Specific to Sarcopenia. <i>Journal of Clinical Medicine</i> , 2018, 7, 323.	1.0	29
124	Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 1139-1140.	1.2	4
125	Evaluation of the Responsiveness of the SarQoL [®] Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia. <i>Advances in Therapy</i> , 2018, 35, 1842-1858.	1.3	23
126	Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. <i>Calcified Tissue International</i> , 2018, 103, 540-545.	1.5	23

#	ARTICLE	IF	CITATIONS
127	Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. <i>Nutrients</i> , 2018, 10, 555.	1.7	186
128	The Authors reply: Dual energy X-ray absorptiometry: gold standard for muscle mass? by Scafoglieri et al.. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 788-790.	2.9	3
129	English translation and validation of the SarQoL [®] , a quality of life questionnaire specific for sarcopenia. <i>Age and Ageing</i> , 2017, 46, 271-276.	0.7	40
130	Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 332-340.	0.5	75
131	Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1126-1135.	3.1	109
132	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017, 69, 1287-1296.	1.5	95
133	Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. <i>Drugs and Aging</i> , 2017, 34, 359-365.	1.3	37
134	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. <i>Rheumatology</i> , 2017, 56, 1167-1176.	0.9	26
135	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017, 7, 1-12.	1.0	181
136	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 513-523.	5.5	635
137	A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention. <i>Archives of Osteoporosis</i> , 2017, 12, 57.	1.0	15
138	Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONDroitin versus CElecoxib versus Placebo Trial (CONCEPT). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1537-1543.	0.5	75
139	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). <i>Endocrine</i> , 2017, 56, 245-261.	1.1	52
140	Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). <i>Archives of Osteoporosis</i> , 2017, 12, 1.	1.0	72
141	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619.	0.2	5
142	Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1811-1813.	0.9	7
143	International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e10.	1.6	6
144	Current review of the SarQoL [®] : a health-related quality of life questionnaire specific to sarcopenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 335-341.	0.7	30

#	ARTICLE	IF	CITATIONS
145	How clinical practitioners assess frailty in their daily practice: an international survey. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 905-912.	1.4	54
146	Psychometric performance of the Romanian version of the SarQoL [®] , a health-related quality of life questionnaire for sarcopenia. <i>Archives of Osteoporosis</i> , 2017, 12, 103.	1.0	26
147	Micro factors bringing the pharmaceutical industry to a seismic shaking <i>a qualitative research</i>. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 267-274.	0.7	1
148	Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study. <i>Calcified Tissue International</i> , 2017, 101, 465-472.	1.5	3
149	Adherence to a Mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative. <i>Clinical Nutrition</i> , 2017, 36, 1609-1614.	2.3	61
150	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. <i>Maturitas</i> , 2017, 96, 54-57.	1.0	51
151	Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 1055-1064.	1.3	13
152	Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0169548.	1.1	737
153	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. <i>Oncotarget</i> , 2017, 8, 75646-75663.	0.8	53
154	Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. <i>JMIR Research Protocols</i> , 2017, 6, e76.	0.5	21
155	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.5	26
156	Re: Kucharz EJ, Kovalenko V, Szınt3 S, etal. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. <i>Curr Med Res Opin</i> 2016;32:997-1004. <i>Current Medical Research and Opinion</i> , 2016, 32, 1771-1772.	0.9	0
157	Sarcopenia in daily practice: assessment and management. <i>BMC Geriatrics</i> , 2016, 16, 170.	1.1	468
158	Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 571-578.	0.7	9
159	Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis. <i>Advances in Therapy</i> , 2016, 33, 2257-2268.	1.3	15
160	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	1.4	22
161	Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S12-S17.	1.6	73
162	High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. <i>Journal of Rheumatology</i> , 2016, 43, 657-665.	1.0	16

#	ARTICLE	IF	CITATIONS
163	Optimizing the management of osteoarthritisâ€”Transitioning evidence-based guidelines into practical guidance for real-world clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S1-S2.	1.6	3
164	Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S28-S33.	1.6	138
165	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	1.3	116
166	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritisâ€”From evidence-based medicine to the real-life setting. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S3-S11.	1.6	203
167	Osteoporosis and sarcopenia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2016, 19, 31-36.	1.3	171
168	A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. <i>Current Medical Research and Opinion</i> , 2016, 32, 997-1004.	0.9	44
169	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 47-58.	1.4	91
170	The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PREvention of knee Osteoarthritis in Overweight Females (PROOF) study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S42-S48.	1.6	23
171	Effects of Dairy Products Consumption on Health: Benefits and Beliefsâ€”A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. <i>Calcified Tissue International</i> , 2016, 98, 1-17.	1.5	210
172	Patientsâ€™ Expectations Impact Their Satisfaction following Total Hip or Knee Arthroplasty. <i>PLoS ONE</i> , 2016, 11, e0167911.	1.1	100
173	Self-Medication Practice among Amateur Runners: Prevalence and Associated Factors. <i>Journal of Sports Science and Medicine</i> , 2016, 15, 387-8.	0.7	2
174	Aesthetic discomfort in hand osteoarthritis: results from the LiÃ“ge Hand Osteoarthritis Cohort (LIHOC). <i>Arthritis Research and Therapy</i> , 2015, 17, 346.	1.6	11
175	Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. <i>Archives of Public Health</i> , 2015, 73, 48.	1.0	24
176	Clinical Trials Using Mobile Health Applications. <i>Pharmaceutical Medicine</i> , 2015, 29, 17-25.	1.0	10
177	Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11). <i>Archives of Osteoporosis</i> , 2015, 10, 11.	1.0	11
178	Letter to the Editor. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e15.	1.6	0
179	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. <i>Current Medical Research and Opinion</i> , 2015, 31, 1041-1045.	0.9	22
180	Commentary on recent therapeutic guidelines for osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 611-617.	1.6	88

#	ARTICLE	IF	CITATIONS
181	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. <i>Drugs and Aging</i> , 2015, 32, 179-187.	1.3	82
182	Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. <i>Journal of Orthopaedics</i> , 2015, 12, 46-57.	0.6	9
183	Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 60.	0.8	139
184	Burden of frailty in the elderly population: perspectives for a public health challenge. <i>Archives of Public Health</i> , 2015, 73, 19.	1.0	297
185	Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. <i>Age and Ageing</i> , 2015, 44, 960-966.	0.7	89
186	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. <i>Pharmacoeconomics</i> , 2015, 33, 205-224.	1.7	84
187	Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. <i>European Journal of Public Health</i> , 2015, 25, 20-25.	0.1	41
188	Mobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization. <i>JMIR MHealth and UHealth</i> , 2015, 3, e78.	1.8	33
189	Effects of vitamin D in the elderly population: current status and perspectives. <i>Archives of Public Health</i> , 2014, 72, 32.	1.0	56
190	Cardiac concerns associated with strontium ranelate. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1209-1213.	1.0	64
191	Monitoring of osteoporosis therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 835-841.	2.2	17
192	Sarcopenia: burden and challenges for public health. <i>Archives of Public Health</i> , 2014, 72, 45.	1.0	317
193	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	1.6	29
194	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000515.	1.6	85
195	Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. <i>Current Medical Research and Opinion</i> , 2014, 30, 1165-1176.	0.9	10
196	Smart wearable body sensors for patient self-assessment and monitoring. <i>Archives of Public Health</i> , 2014, 72, 28.	1.0	333
197	Prevalence of vitamin D inadequacy in European women aged over 80 years. <i>Archives of Gerontology and Geriatrics</i> , 2014, 59, 78-82.	1.4	40
198	Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. <i>Arthritis Research and Therapy</i> , 2014, 16, R36.	1.6	44

#	ARTICLE	IF	CITATIONS
199	Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. <i>Rheumatology</i> , 2014, 53, 1457-1464.	0.9	25
200	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 253-263.	1.6	414
201	Gaucher Disease and Bone Manifestations. <i>Calcified Tissue International</i> , 2014, 95, 477-494.	1.5	53
202	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014, 79, 122-132.	1.0	213
203	The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4336-4345.	1.8	503
204	Challenges for the Development of Bone-Forming Agents in Europe. <i>Calcified Tissue International</i> , 2014, 94, 469-473.	1.5	19
205	Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient. <i>Calcified Tissue International</i> , 2014, 95, 94-96.	1.5	17
206	The promise of wearable activity sensors to define patient recovery. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1089-1093.	0.8	85
207	Romosozumab in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2014, 370, 412-420.	13.9	981
208	Health Technology Assessment in Osteoporosis. <i>Calcified Tissue International</i> , 2013, 93, 1-14.	1.5	39
209	Quality of Life in Sarcopenia and Frailty. <i>Calcified Tissue International</i> , 2013, 93, 101-120.	1.5	310
210	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 303-313.	1.6	239
211	How to define responders in osteoarthritis. <i>Current Medical Research and Opinion</i> , 2013, 29, 719-729.	0.9	75
212	Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 179-186.	0.5	252
213	Risk of Hip Fracture in Community-dwelling and Institutionalized Osteoporotic Patients: A 3-year Study. <i>International Journal of Gerontology</i> , 2013, 7, 167-170.	0.7	4
214	Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 807-815.	3.1	9
215	Safety concerns with the long-term management of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 507-522.	1.0	28
216	Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 268-276.	1.2	19

#	ARTICLE	IF	CITATIONS
217	Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. <i>Rheumatology</i> , 2013, 52, 1058-1069.	0.9	15
218	Is there potential for strontium ranelate in the management of osteoarthritis?. <i>Clinical Practice (London, England)</i> , 2013, 10, 201-207.	0.1	1
219	Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. <i>Patient Preference and Adherence</i> , 2013, 7, 133.	0.8	87
220	Dabigatran Etxilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. <i>Blood</i> , 2013, 122, 3633-3633.	0.6	0
221	In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo. <i>Evidence-Based Medicine</i> , 2012, 17, 152-153.	0.6	4
222	Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. <i>Bone</i> , 2012, 50, 289-295.	1.4	55
223	Role of glucosamine in the treatment for osteoarthritis. <i>Rheumatology International</i> , 2012, 32, 2959-2967.	1.5	90
224	Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. <i>Current Medical Research and Opinion</i> , 2012, 28, 231-239.	0.9	41
225	The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland. <i>Value in Health</i> , 2012, 15, 604-612.	0.1	52
226	Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. <i>Calcified Tissue International</i> , 2012, 91, 244-249.	1.5	19
227	Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 694-701.	3.1	290
228	Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis. <i>Drugs</i> , 2011, 71, 65-78.	4.9	90
229	Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium. <i>Pharmacoeconomics</i> , 2011, 29, 895-911.	1.7	61
230	Adverse drug reactions to osteoporosis treatments. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 593-604.	1.3	37
231	Tumor-induced osteomalacia: The tumor may stay hidden!. <i>Clinical Biochemistry</i> , 2011, 44, 1264-1266.	0.8	14
232	Current options for the management of postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2533-2552.	0.9	27
233	Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2011, 89, 91-104.	1.5	170
234	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	0.9	12

#	ARTICLE	IF	CITATIONS
235	Cutaneous Side Effects of Antiosteoporosis Treatments. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 31-41.	1.2	11
236	Oral calcitonin in the management of osteoarthritis: hope or fantasy?. International Journal of Clinical Rheumatology, 2010, 5, 53-58.	0.3	3
237	Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International, 2010, 86, 202-210.	1.5	77
238	Costâ€“Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 2010, 13, 394-401.	0.1	54
239	Interest of lasofoxifene in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 2010, 11, 1773-1775.	0.9	0
240	Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 677-689.	0.7	20
241	Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 133-143.	1.2	4
242	Strontium ranelate: a look back at its use for osteoporosis. Expert Opinion on Pharmacotherapy, 2010, 11, 2915-2927.	0.9	3
243	Costâ€“effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 359-366.	0.7	9
244	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 2010, 96, 170-177.	1.4	56
245	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75Âyears. Bone, 2010, 46, 440-446.	1.4	23
246	Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone, 2010, 46, 1038-1042.	1.4	62
247	Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone, 2010, 47, 34-40.	1.4	37
248	Prevention and treatment of postmenopausal osteoporosis. , 2010, , 83-114.		1
249	Ibandronate in the Management of Postmenopausal Osteoporosis. Clinical Medicine Therapeutics, 2009, 1, CMT.S2354.	0.1	1
250	Longâ€“term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a twoâ€“year, randomized, doubleâ€“blind, placeboâ€“controlled trial. Arthritis and Rheumatism, 2009, 60, 524-533.	6.7	229
251	Strontium ranelate: New data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 2009, 7, 96-102.	1.5	6
252	Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. Value in Health, 2009, 12, 687-696.	0.1	69

#	ARTICLE	IF	CITATIONS
253	Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1253-1263.	6.3	452
254	Low dietary calcium in European postmenopausal osteoporotic women. <i>Public Health Nutrition</i> , 2009, 12, 111-114.	1.1	27
255	Highest Prevalence of Vitamin D Inadequacy in Institutionalized Women Compared with Noninstitutionalized Women: A Case-Control Study. <i>Women's Health</i> , 2009, 5, 49-54.	0.7	29
256	The need for economic evaluation in osteoarthritis. <i>Aging Health</i> , 2009, 5, 591-954.	0.3	1
257	Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 433-438.	3.1	98
258	Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature. <i>Calcified Tissue International</i> , 2008, 82, 288-292.	1.5	75
259	Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. <i>Advances in Therapy</i> , 2008, 25, 1235-1256.	1.3	30
260	Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. <i>Clinical Rheumatology</i> , 2008, 27, 955-960.	1.0	42
261	Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 1687-1695.	6.7	235
262	Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 165.	0.8	61
263	Bone-forming agents in the management of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 869-883.	2.2	23
264	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. <i>Disease Management and Health Outcomes</i> , 2008, 16, 429-438.	0.3	10
265	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. <i>Bone</i> , 2008, 42, 841-847.	1.4	189
266	Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. <i>Bone</i> , 2008, 42, 832-836.	1.4	48
267	Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. <i>Bone</i> , 2008, 43, 343-347.	1.4	57
268	Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. <i>Current Medical Research and Opinion</i> , 2008, 24, 207-213.	0.9	73
269	Ibandronate in profile: drug characteristics and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 941-951.	1.5	5
270	Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture. <i>Journal of Bone and Joint Surgery - Series A</i> , 2008, 90, 2142-2148.	1.4	127

#	ARTICLE	IF	CITATIONS
271	Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. <i>Journal of Rheumatology</i> , 2008, 35, 488-97.	1.0	99
272	Symptom and Structure Modifying Properties of Chondroitin Sulfate in Osteoarthritis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 1051-1061.	1.1	18
273	Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3076-3081.	1.8	119
274	Injectable Bisphosphonates for the Treatment of Osteoporosis. <i>Women's Health</i> , 2007, 3, 719-723.	0.7	1
275	Managing the osteoporotic patient today. <i>Bone</i> , 2007, 40, S12-S18.	1.4	5
276	Calcium and vitamin D for osteoporotic fracture risk. <i>Lancet, The</i> , 2007, 370, 632-634.	6.3	13
277	Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis. <i>Drugs and Aging</i> , 2007, 24, 573-580.	1.3	115
278	Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis. <i>Drugs and Aging</i> , 2007, 24, 351-359.	1.3	13
279	Strontium ranelate normalizes bone mineral density in osteopenic patients. <i>Aging Clinical and Experimental Research</i> , 2007, 19, 330-333.	1.4	11
280	Highlights from The Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1779-1784.	0.9	0
281	The efficacy of glucosamine sulfate in osteoarthritis: Financial and nonfinancial conflict of interest. <i>Arthritis and Rheumatism</i> , 2007, 56, 2105-2110.	6.7	64
282	Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. <i>BMC Public Health</i> , 2007, 7, 64.	1.2	30
283	The Treatment of Severe Postmenopausal Osteoporosis. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006, 5, 15-23.	1.8	11
284	Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. <i>Current Medical Research and Opinion</i> , 2006, 22, 61-66.	0.9	110
285	Intravenous Ibandronate in the Treatment of Osteoporosis. <i>Drugs</i> , 2006, 66, 1602-1603.	4.9	1
286	Adherence and persistence: Impact on outcomes and health care resources. <i>Bone</i> , 2006, 38, 18-21.	1.4	42
287	Osteoporosis: A still increasing prevalence. <i>Bone</i> , 2006, 38, 4-9.	1.4	763
288	Strontium Ranelate. <i>Clinical Orthopaedics and Related Research</i> , 2006, 443, 55-60.	0.7	29

#	ARTICLE	IF	CITATIONS
289	Raloxifene Reduces Fractures in Postmenopausal Women with Osteoporosis. <i>Clinical Orthopaedics and Related Research</i> , 2006, 443, 48-54.	0.7	22
290	Adherence to anti-osteoporotic treatment: does it really matter?. <i>Future Rheumatology</i> , 2006, 1, 37-40.	0.2	11
291	Vertebral Fracture Risk Reduction With Strontium Ranelate in Women With Postmenopausal Osteoporosis Is Independent of Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 536-542.	3.1	111
292	Strontium Ranelate Reduces the Risk of Vertebral and Nonvertebral Fractures in Women Eighty Years of Age and Older. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1113-1120.	3.1	177
293	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , 2006, 17, 159-166.	1.3	33
294	Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. <i>Osteoporosis International</i> , 2006, 17, 1-7.	1.3	39
295	Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. <i>Osteoporosis International</i> , 2006, 17, 8-19.	1.3	116
296	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006, 54, 2339-2341.	6.7	5
297	Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1838-1846.	6.7	240
298	Developments in the pharmacotherapeutic management of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1603-1615.	0.9	31
299	Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. <i>Clinical Interventions in Aging</i> , 2006, 1, 415-423.	1.3	34
300	Assessment of structure-modifying drugs in osteoarthritis: surrogate or hard clinical end points?. <i>Future Rheumatology</i> , 2006, 1, 199-206.	0.2	0
301	Direct and indirect costs attributable to osteoarthritis in active subjects. <i>Journal of Rheumatology</i> , 2006, 33, 1152-8.	1.0	56
302	Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1315-1322.	3.1	288
303	Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. <i>Osteoporosis International</i> , 2005, 16, 239-254.	1.3	64
304	Strontium ranelate: A new treatment for postmenopausal osteoporosis with a dual mode of action. <i>Current Osteoporosis Reports</i> , 2005, 3, 30-34.	1.5	25
305	Glucosamine Sulphate in Osteoarthritis: From Symptoms to Structure Modification. <i>Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents</i> , 2005, 4, 217-220.	0.4	0
306	Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Postmenopausal Women: Results from the Monthly Oral Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5018-5024.	1.8	52

#	ARTICLE	IF	CITATIONS
307	Is there Any Interest in Combining Treatments in Osteoporosis?. <i>Current Rheumatology Reviews</i> , 2005, 1, 49-55.	0.4	7
308	Treatment of postmenopausal osteoporosis. <i>BMJ: British Medical Journal</i> , 2005, 330, 859-860.	2.4	16
309	The high prevalence of inadequate serum vitamin D levels and implications for bone health. <i>Current Medical Research and Opinion</i> , 2005, 21, 579-585.	0.9	91
310	Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2301-2313.	0.9	0
311	Once-Monthly Ibandronate. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 389-390.	1.8	0
312	Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss. <i>Journal of rheumatology Supplement, The</i> , 2005, 76, 21-5.	2.2	0
313	Current concepts in the therapeutic management of osteoarthritis with glucosamine. <i>Bulletin of the Hospital for Joint Diseases</i> , 2005, 63, 31-6.	0.3	4
314	Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis. <i>Archives of Internal Medicine</i> , 2004, 164, 2024.	4.3	275
315	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 263-268.	0.6	117
316	Strontium ranelate: a new paradigm in the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 857-864.	1.9	23
317	Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. <i>Osteoporosis International</i> , 2004, 15, 301-310.	1.3	112
318	Combination/sequential therapy in osteoporosis. <i>Current Osteoporosis Reports</i> , 2004, 2, 123-130.	1.5	14
319	Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. <i>Aging Clinical and Experimental Research</i> , 2004, 16, 389-397.	1.4	13
320	Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening?. <i>Aging Clinical and Experimental Research</i> , 2004, 16, 413-419.	1.4	1
321	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2004, 350, 459-468.	13.9	1,465
322	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004, 11, 138-143.	0.8	104
323	Combination/sequential therapy in osteoporosis. <i>Current Osteoporosis Reports</i> , 2004, 2, 123-130.	1.5	2
324	Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 394-401.	3.1	190

#	ARTICLE	IF	CITATIONS
325	Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. <i>Osteoporosis International</i> , 2003, 14, 179-190.	1.3	110
326	Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. <i>Osteoporosis International</i> , 2003, 14, 741-749.	1.3	29
327	Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. <i>Maturitas</i> , 2003, 44, 259-265.	1.0	50
328	Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis. <i>Archives of Internal Medicine</i> , 2003, 163, 1514.	4.3	309
329	Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. <i>Current Opinion in Rheumatology</i> , 2003, 15, 651-655.	2.0	23
330	New perspectives in the management of osteoarthritis. structure modification: facts or fantasy?. <i>Journal of rheumatology Supplement, The</i> , 2003, 67, 14-20.	2.2	6
331	Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 985-992.	1.8	209
332	Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3609-3617.	1.8	490
333	Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2001, 344, 1434-1441.	13.9	4,090
334	Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2001, 357, 251-256.	6.3	1,116
335	Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. <i>New England Journal of Medicine</i> , 2001, 344, 333-340.	13.9	1,831
336	Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium. <i>Pharmacoeconomics</i> , 1999, 15, 507-514.	1.7	71
337	Promising New Agents in Osteoporosis. <i>Drugs in R and D</i> , 1999, 1, 195-201.	1.1	5
338	Increased number of hip fractures. <i>Lancet, The</i> , 1999, 353, 2160-2161.	6.3	16
339	The Use of Different Dual X-Ray Absorptiometry Brands in a Multicenter Clinical Trial. <i>Journal of Clinical Densitometry</i> , 1999, 2, 37-44.	0.5	30
340	Current status of fluoride salts to treat postmenopausal osteoporosis. <i>Current Opinion in Orthopaedics</i> , 1998, 9, 7-10.	0.3	1
341	The Effect of Sodium Monofluorophosphate plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. <i>Annals of Internal Medicine</i> , 1998, 129, 1.	2.0	86
342	Calcitonin for prevention and treatment of osteoporosis. <i>American Journal of Medicine</i> , 1993, 95, S44-S47.	0.6	68

#	ARTICLE	IF	CITATIONS
343	Minimal levels of serum estradiol prevent postmenopausal bone loss. <i>Calcified Tissue International</i> , 1992, 51, 340-343.	1.5	63
344	Effect of calcitonin on bone mass and fracture rates. <i>American Journal of Medicine</i> , 1991, 91, S19-S22.	0.6	40
345	Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis. , 0, .		85